



# CLINICIAN-TO-CLINICIAN ADVICE

## How Much DAA Treatment is Enough? Outcomes From a Large Case Series of HCV Treatment Interruptions

Astha Kanani, MD; Christopher Bositis, MD, AAHIVS;  
Carolyn Chu, MD, AAHIVS; Sean Brennan

# Authors



**Astha Kanani, MD**

Clinician Consultant, NCCC



**Chris Bosisis, MD, AAHIVS**

Clinical Director, NCCC

Clinical Associate Professor of Family and Community Medicine



**Carolyn Chu, MD, MSc FAAFP, AAHIVS**

Principal Investigator, NCCC

Professor of Clinical Family Community Medicine

# Background and Objectives

- Simplified therapy with direct-acting antivirals (DAAs) has greatly expanded low-barrier hepatitis C virus (HCV) care including primary care-based treatment.
- Despite short treatment duration, treatment interruptions are common and there is a paucity of data to guide clinical management.<sup>1,2,3,4</sup>
- The National Clinician Consultation Center (NCCC) reviewed cases of HCV treatment interruption received on its national Hepatitis C Warmline and describes clinical outcomes after treatment interruption.

# Methods

- The NCCC is a federally funded education and capacity-building resource that provides free, telephone-based consultation to any U.S. healthcare provider seeking guidance on HCV prevention, diagnosis, and treatment.
- Deidentified case information is provided by callers and documented within the NCCC's secure consultation database, along with consultant recommendations.
- Calls involving HCV treatment interruptions received between September 1, 2022, to August 31, 2023, were retrospectively identified and reviewed for clinical information including genotype, fibrosis score, prior DAA treatment experience, number/timing of missed doses, DAA interruption management, care setting, NCCC consultant recommendations, and SVR12 outcomes.



How Much DAA Treatment is Enough?  
Outcomes From a Large Case Series  
of HCV Treatment Interruptions

# Results

# Results

- During the review period, 61 out of 541 calls (11%) to NCCC's Hepatitis C Warmline involved cases of DAA treatment interruption.
- Patient age ranged from 20-76 with a median age of 47.
- 82% of the calls were from an outpatient community-based care setting and 11% were from providers serving patients/communities in Indian Country.

# Results

In this case series of 61 patients with HCV treatment interruption from mostly primary care health settings, of available outcome data, we found that SVR rates were high (90%) despite a wide range of missed doses of DAA therapy.

23/32 patients: had no SVR data due to patient being lost to follow up

9/32 patients: NCCC unable to reach provider to confirm follow-up information

## Reasons for patient loss to follow-up

- Incarceration
- Pharmacy delivery issues
- Side effects
- Unstable housing
- Unstable mental health
- Substance use



# Results

## HCV DAA Treatment Regimen




Fig. 1

## CALLER IDENTIFIED PATIENT GENDER




Fig. 2

# Results

### Reported Fibrosis Staging (N=61)




Fig. 3

### REPORTED PATIENT GENOTYPE

■ 1 a or b ■ 2 ■ 3 ■ Indeterminate ■ Unknown





Fig. 4

# Results

## SVR DATA ABLE TO BE OBTAINED



■ Yes ■ No

Fig. 5

## SVR Achievement for the Calls with Available Outcome Data




Fig. 6

Table 1: Characteristics of patients with one round of DAA treatment with SVR data

Characteristics	Treatment naïve, SVR12 available (n= 21)	Timing of Treatment Interruption	
		Day 1-28 (n=3)	After Day 28 (n=18)
<b>Genotype</b>			
1	11	3	8
2	1	0	1
3	4	0	4
Other/unknown	5	0	5
<b>Fibrosis score</b>			
F1-F3	17	3	14
F4	2	0	2
Unknown	2	0	2
<b>DAA regimen</b>			
G/P	15	2	13
SOF/VEL	4	1	3
Other	2	0	2
<b>% doses missed*</b>			
Median	31%	25%	37.5%
Range	9-67%	12-30%	9-67%
<b>Achieved SVR12</b>	19/21 (93%)	3/3 (100%)	16/18 (89%)

\*When known. Late = missed dose

# Table 2: Characteristics of patients with multiple rounds of DAA treatment with SVR data

Patient Age/Gender	Genotype	Fibrosis Staging	DAA Treatment Description	% Missed Doses	Treatment Interruption reasons	SVR Achieved?
54 trans-female	1a	F1	<ul style="list-style-type: none"> <li>1<sup>st</sup> round - G/P in 7/2022</li> <li>2<sup>nd</sup> round - SOF/VEL in 3/2023*</li> </ul>	<ul style="list-style-type: none"> <li>81% missed first round</li> <li>Had some gaps, unknown quantity</li> </ul>	<ul style="list-style-type: none"> <li>Relapse w/ meth use</li> <li>Mental health struggle</li> </ul>	Yes
36 cis-male	1a	No cirrhosis	<ul style="list-style-type: none"> <li>1<sup>st</sup> round - SOF/VEL in 4/2021</li> <li>2<sup>nd</sup> round - G/P 3/22*</li> </ul>	<ul style="list-style-type: none"> <li>58% missed first round</li> <li>12.5% missed 2<sup>nd</sup> round</li> </ul>	<ul style="list-style-type: none"> <li>Relapse w/ meth use</li> <li>Relapse w/ opioid use</li> </ul>	Yes
52 cis-male	1a	F4	<ul style="list-style-type: none"> <li>1<sup>st</sup> round - G/P in 2019</li> <li>2<sup>nd</sup> round - SOF/VEL/VOX in 2/2023</li> </ul>	<ul style="list-style-type: none"> <li>50% missed first round</li> <li>Unknown missed 2<sup>nd</sup> round</li> </ul>	<ul style="list-style-type: none"> <li>Alcohol use</li> </ul>	Yes
37 cis-male	1a	F4	<ul style="list-style-type: none"> <li>1<sup>st</sup> round - G/P in 2020</li> <li>2<sup>nd</sup> round - SOF/VEL in 11/2022*</li> </ul>	<ul style="list-style-type: none"> <li>87.5% missed first round</li> <li>15.4% missed 2<sup>nd</sup> round</li> </ul>	<ul style="list-style-type: none"> <li>Unknown</li> <li>Incarceration</li> </ul>	Yes
48 cis-female	3	F0	<ul style="list-style-type: none"> <li>1<sup>st</sup> round - SOF/VEL in 2021</li> <li>2<sup>nd</sup> round - SOF/VEL/VOX in 9/2022</li> </ul>	<ul style="list-style-type: none"> <li>66% missed first round</li> <li>Unknown missed 2<sup>nd</sup> round</li> </ul>	<ul style="list-style-type: none"> <li>Alcohol use/GI said stop taking due to Alcohol</li> </ul>	Yes
31 cis-male	1a	F0/F1	<ul style="list-style-type: none"> <li>1<sup>st</sup> round - SOF/VEL in 7/2021</li> <li>2<sup>nd</sup> round - SOF/VEL/VOX in 3/2022*</li> </ul>	<ul style="list-style-type: none"> <li>66% missed first round</li> <li>66% missed second round</li> </ul>	<ul style="list-style-type: none"> <li>Relapse w/ meth use</li> <li>Relapse w/ opioid use</li> <li>Unhoused</li> </ul>	Yes
54 cis-male	1a	F3	<ul style="list-style-type: none"> <li>1<sup>st</sup> round - Unknown DAA 2010</li> <li>2<sup>nd</sup> round - G/P in 2018</li> <li>3<sup>rd</sup> round - G/P 2/2023*</li> </ul>	<ul style="list-style-type: none"> <li>Unknown missed first round</li> <li>75% missed second round</li> <li>0% missed third round</li> </ul>	<ul style="list-style-type: none"> <li>Traveling for job</li> <li>Alcohol use</li> </ul>	Yes
48 cis-male	3	No cirrhosis	<ul style="list-style-type: none"> <li>First round - SOF/VEL in 2022 - took 4 weeks</li> <li>Second round - SOF/VEL in 6/2023*</li> </ul>	<ul style="list-style-type: none"> <li>66% missed first round</li> <li>Unknown % - provider thinks completed 12 weeks</li> </ul>	<ul style="list-style-type: none"> <li>Stomach upset</li> <li>None reported</li> </ul>	No

\* Did not match with treatment interruption recommendations published by American Association for the Study of Liver Diseases at that time.

# Conclusions

- This series of over 60 HCV treatment interruption cases provides additional “real world” data including SVR12 outcomes.
- Despite a wide range of missed doses, with many cases treated through primary care clinics and other low-barrier settings, 90% with available follow-up data achieved cure.
- Of eight cases undergoing retreatment, 88% were able to achieve SVR. First line DAA’s were “recycled” in 5/8 of these patients.
- Of 32 patients with missing follow-up information regarding SVR12 outcomes, the majority (72%) was due to patient loss to follow-up—this highlights the importance of early identification of those at risk for, and interventions to prevent, loss to follow-up.
- For cases with available follow-up and SVR12 information, our results affirm SVR12 occurs even with “imperfect” DAA adherence
- Limitations of our study: information relied on provider review and recall, which may have impacted data accuracy and completeness
- More research on the role of “recycling” first-line DAAs is needed, as well as additional information on optimal management of HCV treatment interruptions

# References

- 1) Fabbiani M, Lombardi A, Colaneri M, et al. [High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting](#). J Viral Hepat. 2021;28(3):558-568.
- 2) Cunningham EB, Amin J, Feld JJ, et al. [Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study](#). Int J Drug Policy. 2018;62:14-23.
- 3) Rosenthal ES, Silk R, Mathur P, Gross C, Eyasu R, Nussdorf L, Hill K, Brokus C, D'Amore A, Sidique N, Bijole P, Jones M, Kier R, McCullough D, Sternberg D, Stafford K, Sun J, Masur H, Kottlilil S, Kattakuzhy S. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. Clin Infect Dis. 2020 Oct 23;71(7):1715-1722. doi: 10.1093/cid/ciaa105. PMID: 32009165; PMCID: PMC7755091.
- 4) <https://www.hcvguidelines.org/evaluate/monitoring#incomplete-adherence>



The National Clinician Consultation Center is a free telephone advice service for clinicians, by clinicians. Please check out [nccc.ucsf.edu](http://nccc.ucsf.edu) for more information.

**HIV/AIDS Warmline**  
**800-933-3413**

HIV treatment, ARV management, complications, and co-morbidities

**Perinatal HIV Hotline**  
**888-448-8765**

Pregnancy, infant feeding and HIV

**Hepatitis C Warmline**  
**844-HEP-INFO/  
844-437-4636**

HCV testing, staging, monitoring, treatment

**Substance Use Warmline**  
**855-300-3595**

Substance use evaluation and management

**PrEPline**  
**855-HIV-PrEP**

HIV pre-exposure prophylaxis

**PEPline**  
**888-448-4911**

Occupational & non-occupational exposure management

*This National Clinician Consultation Center program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$2,633,756 with 0% financed with non-governmental sources.*

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit [HRSA.gov](http://HRSA.gov).*

# Acknowledgement

This National Clinician Consultation Center program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$3,236,220 with 0% financed with non-governmental sources.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit [HRSA.gov](http://HRSA.gov).



# Disclaimer

Funding for this presentation was made possible [in part, if applicable] by U1OHA30039 from the Human Resources and Services Administration HIV/AIDS Bureau. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. *Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.*



Thank you!

To learn more, please visit  
**[nccc.ucsf.edu](https://nccc.ucsf.edu)**

Follow the NCCC:    